• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
VCYT

VCYT

Veracyte, Inc.

NASDAQHealthcareBiotechnologyUS

USD48.69

+0.89 (+1.86%)

Rating:B+

Company Profile

CEO

Marc A. Stapley

IPO Date

2013-10-30

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$47.77

Prev. Close

$47.80

Day Low

$46.49

Day High

$49.40

52W Low

$22.61

52W High

$50.71

Market Cap

$3.89B

Volume

1.45M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

25.5%

Avg Negative

19.8%

Avg Neutral

54.9%

News Feed

Veracyte, Inc. (VCYT) CEO Marc Stapley on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·7/29/2021·↓ negative

Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·7/29/2021·↑ positive

Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021

Business Wire·7/8/2021·↓ negative

Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team

Business Wire·7/1/2021·↑ positive

New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte's Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer

Business Wire·6/14/2021·↑ positive

Moving Average Crossover Alert: Veracyte (VCYT)

Zacks Investment Research·6/9/2021·↓ negative

Veracyte: Tumultuous Times

Seeking Alpha·6/6/2021·↓ negative

Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder

Business Wire·6/4/2021·↑ positive

CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences

Business Wire·6/2/2021·↑ positive

Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition

Benzinga·6/1/2021·↑ positive